 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
||||||||||||||||||||||||||||||||||
 |
Ireland Laboratories Adopt ThinPrep(R) Pap Test Exclusively
MARLBOROUGH, Mass., (Mar 2, 2006) - Cytyc Corporation, a leading women's health company, today announced that all laboratories performing cervical cancer screening in Ireland are adopting the ThinPrep(R) Pap Test. Most of the laboratories in Ireland had completed the conversion process last year, including the installation of a ThinPrep(R) Imaging System at the University of Dublin, Trinity College. Cytyc's Irish distributor, Screenlink, recently won the tender for the remaining two laboratories in Cork and Galway making Cytyc the exclusive supplier of liquid-based cytology in Ireland, where approximately 250,000 Pap tests are performed annually. Currently about 150,000 tests have been converted to the ThinPrep Pap Test and the remainder is expected to be converted in the next few months. "The recently completed agreements with laboratories in Galway and Cork make the choice of ThinPrep Pap Test unanimous in Ireland," said David Harding, president Cytyc International. "This is clearly a tribute to our technology, as well as the dedicated efforts of our team at Cytyc UK, and Screenlink, our exclusive distributor in Ireland." About HologicHologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic’s core business units are focused on mammography and breast biopsy, osteoporosis assessment, and mini C-arm and extremity MRI imaging for orthopedic applications. Cytyc’s products cover a range of cancer and women’s health applications, including cervical cancer screening, preterm birth screening, treatment of excessive menstrual bleeding, radiation treatment of patients with early-stage breast cancer. Forward-Looking Statements Forward-looking statements in this press release are made pursuant to the provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements relating to Cytyc's future financial condition, operating results and economic performance, and management's expectations regarding key customer relationships, future growth opportunities, product acceptance and business strategy, constitute forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from those statements. Risks and uncertainties include, among others, dependence on key personnel and customers as well as reliance on proprietary technology, uncertainty of product development efforts and product acceptance, management of growth and product diversification, entry into new market segments domestically and new markets internationally, risks associated with litigation, the effective integration of acquired businesses and technologies, competition and competitive pricing pressures, risks associated with the FDA regulatory approval processes and healthcare reimbursement policies in the United States and abroad, introduction of technologies that are disruptive to Cytyc's business and operations, the impact of new accounting requirements and governmental rules and regulations, as well as other risks detailed in Cytyc's filings with the Securities and Exchange Commission, including under the heading "Risk Factors" in its 2005 Annual Report on Form 10-K filed with the Commission. Cytyc cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Cytyc disclaims any obligation to publicly update or revise any such statements to reflect any change in its expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
|
||||||||||||||||||||||||||||||||||||||||
 |
 |
||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
| Home | Women's Health | R2 CAD | Suros Surgical | Skeletal Health | OEM Solutions | Customer Care Center | |||||||||||||||||||||||||||||||||||||||||
| Learning
Center | News & Events | Investor
Relations | About Hologic More Information | Locate Us | Terms of Use | Privacy Policy Copyright 2007 Hologic, Inc. All Rights Reserved. |
|||||||||||||||||||||||||||||||||||||||||